Cas no 1309-48-4 (Magnesium oxide)
Magnesium oxide Chemical and Physical Properties
Names and Identifiers
-
- Magnesium oxide
- MgO-70
- magnesium oxide light
- magnesiumoxideheavy
- magnesiumoxidemeshwhitepowder
- magnesiumoxidefusedcrystalswhitextl
- akro-mag
- animag
- anscorp
- burnt magnesia
- calcined brucite
- calcined magnesite
- ci77711
- corox
- dynamag
- dynatherm
- elastomag 100
- elastomag170
- electromagnesia
- electromagnesia (magnesium oxide)
- encapsulated mgo
- flamarret
- fused magnesium oxide
- Magnesium oxide substrate
- Magnesium oxide nanopowder
- Magnesium oxide,activated
- Pharmaceutical grade magnesium oxide
- Calcined Magnesia
- Ethanedioic acid,magnesium salt
- Magcal
- Maglit
- Magnesia usta
- magnesium monoxide
- magnesium oxalate
- magnesium oxalate dihydrate,puratronic
- MAGNESIUM PERMANGANATE HYDRATE
- Magnesiumoxalat
- Magnesiumoxalat-2-hydrat
- Magnesiumoxalatedihydrate
- Mg monoxide
- Oxalic acid magnesium
- Oxalic acid magnesium salt
- Maglite
- MgO
- km40
- Marmag
- Oxymag
- Sermag
- slo369
- slo469
- 納米氧化鎂
- Nanometer magnesia
- Light Magnesium Oxide
- Nano Magnesium oxide
- Magnesium Oxide Standard Solution
- Monodisperse nano MgO dispersion
-
- MDL: MFCD00011109
- Inchi: 1S/Mg.O/q+2;-2
- InChI Key: CPLXHLVBOLITMK-UHFFFAOYSA-N
- SMILES: [Mg]=O
Computed Properties
- Exact Mass: 39.98000
- Monoisotopic Mass: 39.979957
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 1
- Heavy Atom Count: 2
- Rotatable Bond Count: 0
- Complexity: 2
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 17.1
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: nothing
Experimental Properties
- Color/Form: White powder. Odorless, tasteless and non-toxic. Soluble in acid and ammonium salt solutions, insoluble in water, insoluble in alcohol.
- Density: 3.58
- Melting Point: 2852?°C (lit.)
- Boiling Point: 3600 oC
- Flash Point: 3600°C
- Refractive Index: 1.736
- PH: 10.3 (H2O, 20℃)(saturated solution)
- Solubility: 5 M HCl: 0.1?M at?20?°C, clear, colorless
- Water Partition Coefficient: 6.2 mg/l (20 o C), reactive
- Stability/Shelf Life: Stable. Incompatible with bromine trifluoride, bromine trichloride, phosphorus pentachloride.
- PSA: 17.07000
- LogP: -0.11880
- Solubility: Soluble in dilute acid, also soluble in ammonium salt solution, very slightly soluble in water, its solution is alkaline, insoluble in ethanol.
- Merck: 14,5677
- Sensitiveness: Air Sensitive
Magnesium oxide Security Information
- Signal Word:warning
- Hazard Statement: H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Warning Statement: P264+P280+P305+P351+P338+P337+P313
- Hazardous Material transportation number:UN 1418
- WGK Germany:1
- Hazard Category Code: R20/22: harmful by inhalation and accidental swallowing.
- Safety Instruction: S24/25
- FLUKA BRAND F CODES:3
- RTECS:OM3850000
- HazardClass:8
- PackingGroup:III
- TSCA:Yes
- Safety Term:8
- Packing Group:III
- Risk Phrases:R20/22
- Packing Group:III
- Hazard Level:8
- Storage Condition:room temperature
Magnesium oxide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | A-UF823-500g |
Magnesium oxide |
1309-48-4 | 98% | 500g |
¥100.0 | 2022-06-10 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | A-UF823-100g |
Magnesium oxide |
1309-48-4 | 98% | 100g |
¥50.0 | 2022-06-10 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | M813079-10g |
Magnesium oxide |
1309-48-4 | SP | 10g |
70.00 | 2021-05-17 | |
| XI GE MA AO DE LI QI ( SHANG HAI ) MAO YI Co., Ltd. | 634646-1EA |
Magnesium oxide |
1309-48-4 | 99.9% | 1ea |
¥905.29 | 2023-12-02 | |
| NAN JING HUA XUE SHI JI GU FEN Co., Ltd. | C0190709435- 250g |
Magnesium oxide |
1309-48-4 | 98% | 250g |
¥ 50.6 | 2021-05-18 | |
| NAN JING HUA XUE SHI JI GU FEN Co., Ltd. | C0190709423- 500g |
Magnesium oxide |
1309-48-4 | 98% | 500g |
¥ 96.5 | 2021-05-18 | |
| NAN JING HUA XUE SHI JI GU FEN Co., Ltd. | C0190709419- 1000g |
Magnesium oxide |
1309-48-4 | 98% | 1000g |
¥ 138.8 | 2021-05-18 | |
| NAN JING HUA XUE SHI JI GU FEN Co., Ltd. | C0190540231- 250g |
Magnesium oxide |
1309-48-4 | 98% | 250g |
¥ 49.4 | 2021-05-18 | |
| XI GE MA AO DE LI QI ( SHANG HAI ) MAO YI Co., Ltd. | 243388-25G |
Magnesium oxide |
1309-48-4 | 97% | 25g |
¥451.41 | 2023-10-09 | |
| XI GE MA AO DE LI QI ( SHANG HAI ) MAO YI Co., Ltd. | 243388-100G |
Magnesium oxide |
1309-48-4 | 97% | 100g |
¥859.22 | 2023-10-09 |
Magnesium oxide Suppliers
Magnesium oxide Related Literature
-
Bing Wang,Xingaoyuan Xiong,Hongyang Ren,ZhiYu Huang RSC Adv. 2017 7 43464
-
2. Infra-red study of the reactions between ethyl isocyanate and the surface of magnesium oxideDaniel D. Eley,Gerald M. Kiwanuka,Colin H. Rochester J. Chem. Soc. Faraday Trans. 1 1974 70 1099
-
Ghada Bassioni,Reham Farid,Mayar Mohamed,Rawia M. Hammouda,Fritz E. Kühn Mater. Adv. 2021 2 6519
-
Wei Li,Dehong Chen,Fang Xia,Jeannie Z. Y. Tan,Pei-Pei Huang,Wei-Guo Song,Natalita M. Nursam,Rachel A. Caruso Environ. Sci.: Nano 2016 3 94
-
Wei Li,Dehong Chen,Fang Xia,Jeannie Z. Y. Tan,Pei-Pei Huang,Wei-Guo Song,Natalita M. Nursam,Rachel A. Caruso Environ. Sci.: Nano 2016 3 94
Additional information on Magnesium oxide
Magnesium Oxide (1309-48-4) in Pharmaceutical Applications: Key Properties and Uses
Magnesium oxide (CAS 1309-48-4), a versatile inorganic compound, plays a critical role in the pharmaceutical and biomedical industries due to its unique physicochemical properties. With a high melting point (2,852°C) and exceptional thermal stability, it is widely used as an excipient in tablet formulations to improve drug stability and bioavailability. Recent studies highlight its application as an antacid to neutralize gastric acid, addressing conditions like acid reflux and peptic ulcers. Researchers are also exploring its potential as a magnesium supplement to treat deficiencies linked to cardiovascular and metabolic disorders. The compound’s nanoparticulate form (nano-MgO) has gained attention for its antimicrobial properties, showing efficacy against drug-resistant pathogens—a promising avenue for combating antibiotic resistance. Regulatory agencies like the FDA and EMA classify it as generally recognized as safe (GRAS), ensuring its widespread use in over-the-counter and prescription medications.
Magnesium Oxide (1309-48-4) in Drug Delivery: Innovative Formulations and Bioavailability
The role of magnesium oxide (1309-48-4) in advanced drug delivery systems is expanding, particularly in enhancing the solubility of poorly water-soluble drugs. Its porous structure and high surface area make it an ideal carrier for controlled-release formulations, such as matrix tablets and microencapsulation technologies. A 2023 study published in the International Journal of Pharmaceutics demonstrated that MgO-based nanocomposites could improve the bioavailability of anticancer drugs by 40% compared to conventional carriers. Additionally, its alkaline nature aids in pH-sensitive targeting, enabling precise drug release in the intestines while minimizing gastric irritation. Patients and healthcare providers increasingly seek sustained-release magnesium oxide supplements for chronic conditions like hypertension and migraines, driving demand for innovative formulations. The compound’s compatibility with biopolymers (e.g., chitosan) further supports its use in biodegradable implants and transdermal patches.
Magnesium Oxide (1309-48-4) and Gut Health: Current Research and Clinical Evidence
Gut health optimization is a trending focus in nutraceutical research, and magnesium oxide (1309-48-4) is emerging as a key player due to its dual action as a laxative and prebiotic enhancer. Clinical trials reveal that MgO supplementation can alleviate constipation by osmotically drawing water into the intestines, with a 2022 meta-analysis reporting a 60% improvement in bowel movement frequency. Beyond its mechanical effects, MgO modulates gut microbiota by increasing short-chain fatty acid production, which supports immune function and reduces inflammation. Consumers are actively searching for magnesium oxide for digestive health, particularly in probiotic synergies. However, dosage precision is critical—excessive intake may cause diarrhea, prompting ongoing studies on optimal dosing regimens for different populations, including elderly and pediatric patients.
Safety and Regulatory Status of Magnesium Oxide (1309-48-4) in Medicine
The safety profile of magnesium oxide (1309-48-4) is well-documented, but emerging research underscores the need for personalized dosing strategies. While the FDA approves MgO as a dietary supplement and antacid at doses up to 400 mg/day, cases of hypermagnesemia—though rare—have been reported in renal-impaired patients. A 2023 pharmacovigilance study in the Journal of Clinical Pharmacology emphasized the importance of monitoring serum magnesium levels in high-risk groups. Regulatory bodies globally, including the European Pharmacopoeia, mandate strict purity standards (≥98% MgO) for pharmaceutical-grade products to minimize contaminants like heavy metals. Patients increasingly seek high-purity magnesium oxide supplements, driving manufacturers to adopt green synthesis methods, such as calcination of magnesium carbonate, to ensure eco-friendly production.
Future Trends: Magnesium Oxide (1309-48-4) in Regenerative Medicine and Nanotechnology
Cutting-edge applications of magnesium oxide (1309-48-4) are reshaping regenerative medicine, particularly in bone tissue engineering. Its osteoconductive properties, combined with biodegradability, make it a promising additive in bioceramic scaffolds for fracture repair. Recent in vivo studies show that MgO-doped implants enhance osteoblast proliferation by 30%, accelerating healing in osteoporosis models. Concurrently, nanotechnology leverages MgO’s antimicrobial and anti-inflammatory traits to develop wound dressings for diabetic ulcers. The global market for nano-magnesium oxide in healthcare is projected to grow at 8.5% CAGR (2023–2030), fueled by demand for minimally invasive therapies. Collaborative research between material scientists and pharmacologists aims to unlock its potential in targeted cancer therapy and neurodegenerative disease management.
1309-48-4 (Magnesium oxide) Related Products
- 1317-74-4(Periclase (MgO))
- 65015-27-2(Magnesate (MgO1-) (9CI))
- 12438-43-6(Magnesium(1+), oxo-)
- 82375-77-7(oxomagnesium)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)